Experimental Drug STC3141 Shows Promise Against Sepsis
Griffith University researchers achieved positive Phase II clinical trial results for STC3141, an experimental sepsis treatment targeting underlying biological mechanisms rather than symptoms alone.
Key Points:
- Phase II trial with 180 sepsis patients in China met primary efficacy endpoints
- STC3141 carbohydrate-based compound delivered intravenously counters harmful molecular surge during sepsis
- Treatment aims to reverse vital organ damage, not merely manage symptoms
Why It Matters: Sepsis affects millions globally with no current targeted therapies addressing root biological drivers of this life-threatening condition.
